Archives of Pharmacal Research

, Volume 40, Issue 5, pp 592–600 | Cite as

Smenospongidine suppresses the proliferation of multiple myeloma cells by promoting CCAAT/enhancer-binding protein homologous protein-mediated β-catenin degradation

  • Seoyoung Park
  • In Hyun Hwang
  • Jiseon Kim
  • Young-Hwa Chung
  • Gyu-Young Song
  • MinKyun NaEmail author
  • Sangtaek OhEmail author
Research Article


Abnormal up-regulation of β-catenin expression is associated with the development and progression of multiple myeloma and is thus a potential therapeutic target. Here, we screened cell-based natural compounds and identified smenospongidine, a metabolite isolated from a marine sponge, as an antagonist of the Wnt/β-catenin signaling pathway. Smenospongidine promoted the degradation of intracellular β-catenin that accumulated via Wnt3a or 6-bromoindirubin-3′-oxime, an inhibitor of glycogen synthase kinase-3β. Consistently, smenospongidine down-regulated β-catenin expression and repressed the levels of β-catenin/T cell factor-dependent genes such as axin2, c-myc, and cyclin D1 in RPMI-8226 multiple myeloma cells. Smenospongidine suppressed proliferation and significantly induced apoptosis in RPMI-8266 cells. In addition, smenospongidine-induced β-catenin degradation was mediated by up-regulating CCAAT/enhancer-binding protein homologous protein (CHOP). These findings indicate that smenospongidine exerts its anti-proliferative activity by blocking the Wnt/β-catenin signaling pathway and may be a potential chemotherapeutic agent against multiple myeloma.


Smenospongidine β-catenin degradation Multiple myeloma CCAAT/enhancer-binding protein homologous protein (CHOP) 



This research was supported by Basic Science Research Program through the National Research Foundation of Korea (NRF) funded by the Korean government (NRF-2015R1A2A2A01004599, NRF-2014R1A2A2A01006793) and the High Value-added Food Technology Development Program (114030-3) funded by the Ministry of Agriculture, Food and Rural Affairs.

Compliance with ethical standards

Conflict of interest

The authors declare that there are no conflicts of interest.

Supplementary material

12272_2017_906_MOESM1_ESM.pptx (64 kb)
Supplementary material 1 (PPTX 63 kb)


  1. Aberle H, Bauer A, Stappert J, Kispert A, Kemler R (1997) β-Catenin is a target for the ubiquitin-proteasome pathway. EMBO J 16:3797–3804CrossRefPubMedPubMedCentralGoogle Scholar
  2. Aoki S, Kong D, Matsui K, Rachmat R, Kobayashi M (2004) Sesquiterpene aminoquinones, from a marine sponge, induce erythroid differentiation in human chronic myelogenous leukemia, K562 cells. Chem Pharm Bull 52:935–937CrossRefPubMedGoogle Scholar
  3. Ashihara E, Kawata E, Nakagawa Y, Shimazaski C, Kuroda J, Taniguchi K, Uchiyama H, Tanaka R, Yokota A, Takeuchi M, Kamitsuji Y, Inaba T, Taniwaki M, Kimura S, Maekawa T (2009) β-Catenin small interfering RNA successfully suppressed progression of multiple myeloma in a mouse model. Clin Cancer Res 15:2731–2738CrossRefPubMedGoogle Scholar
  4. Bharti AC, Donato N, Singh S, Aggarwal BB (2003) Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkBα kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis. Blood 101:1053–1062CrossRefPubMedGoogle Scholar
  5. Cho M, Gwak J, Park S, Won J, Kim DE, Yea SS, Cha IJ, Kim TK, Shin JG, Oh S (2005) Diclofenac attenuates Wnt/beta-catenin signaling in colon cancer cells by activation of NF-Κb. FEBS Lett 579:4213–4218CrossRefPubMedGoogle Scholar
  6. Derksen PW, Tjin E, Meijer HP, Klok MD, MacGillavry HD, van Oers MH, Lokhorst HM, Bloem AC, Clevers H, Nusse R, van der Neut R, Spaargaren M, Pals ST (2004) Illegitimate WNT signaling promotes proliferation of multiple myeloma cells. Proc Natl Acad Sci USA 101:6122–6127CrossRefPubMedPubMedCentralGoogle Scholar
  7. Dignam JD, Lebovitz RM, Roeder RG (1983) Accurate transcription initiation by RNA polymerase II in a soluble extract from isolated mammalian nuclei. Nucleic Acids Res 11:1475–1489CrossRefPubMedPubMedCentralGoogle Scholar
  8. Gupta SC, Patchva S, Aggarwal BB (2013) Therapeutic roles of curcumin: lessons learned from clinical trials. AAPS J 15:195–218CrossRefPubMedGoogle Scholar
  9. Gwak J, Oh J, Cho M, Bae SK, Song IS, Liu KH, Jeong Y, Kim DE, Chung YH, Oh S (2011) Galangin suppresses the proliferation of β-catenin response transcription-positive cancer cells by promoting adenomatous polyposis coli/Axin/glycogen synthase kinase-3β-independent β-catenin degradation. Mol Pharmacol 79:1014–1022CrossRefPubMedGoogle Scholar
  10. Hart MJ, de los Santos R, Albert IN, Rubinfeld B, Polakis P (1998) Downregulation of β-catenin by human Axin and its association with the APC tumor suppressor, β-catenin and GSK3-β. Curr Biol 8:573–581CrossRefPubMedGoogle Scholar
  11. He TC, Sparks AB, Rago C, Hermeking H, Zawel L, da Costa LT, Morin PJ, Vogelstein B, Kinzler KW (1998) Identification of c-MYC as a target of the APC pathway. Science 281:1509–1512CrossRefPubMedGoogle Scholar
  12. Horndasch M, Lienkamp S, Springer E, Schmitt A, Pavenstädt H, Walz G, Gloy J (2006) The C/EBP homologous protein CHOP (GADD153) is an inhibitor of Wnt/TCF signals. Oncogene 25:3397–3407CrossRefPubMedGoogle Scholar
  13. Hwang IH, Oh J, Zhou W, Park S, Kim JH, Chittiboyina AG, Ferreira D, Song GY, Oh S, Na M, Hamann MT (2015) Cytotoxic activity of rearranged drimane meroterpenoids against colon cancer cells via down-regulation of β-catenin expression. J Nat Prod 78:453–461CrossRefPubMedPubMedCentralGoogle Scholar
  14. Jho EH, Zhang T, Domon C, Joo CK, Freund JN, Costantini F (2002) Wnt/β-catenin/Tcf signaling induces the transcription of Axin2, a negative regulator of the signaling pathway. Mol Cell Biol 22:1172–1183CrossRefPubMedPubMedCentralGoogle Scholar
  15. Kondracki ML, Guyot M (1989) Biologically active quinone and hydroquinone sesquiterpenoids from the sponge Smenospongia sp. Tetrahedron 45:1995–2004CrossRefGoogle Scholar
  16. Liu C, Li Y, Semenov M, Han C, Baeg GH, Tan Y, Zhang Z, Lin X, He X (2002) Control of β-catenin phosphorylation/degradation by a dual-kinase mechanism. Cell 108:837–847CrossRefPubMedGoogle Scholar
  17. MacDonald BT, Tamai K, He X (2009) Wnt/β-catenin signaling: components, mechanisms, and diseases. Dev Cell 12:9–26CrossRefGoogle Scholar
  18. Meijer L, Skaltsounis AL, Magiatis P, Polychronopoulos P, Knockaert M, Leost M, Ryan XP, Vonica CA, Brivanlou A, Dajani R, Crovace C, Tarricone C, Musacchio A, Roe SM, Pearl L, Greengard P (2003) GSK-3-selective inhibitors derived from Tyrian purple indirubins. Chem Biol 10:1255–1266CrossRefPubMedGoogle Scholar
  19. Miller JR (2002) The Wnts. Genome Biol 3: REVIEWS3001Google Scholar
  20. Oda T, Wang W, Ukai K, Nakazawa T, Mochizuki M (2007) A sesquiterpene quinone, 5-epi-smenospongine, promotes TNF-α production in LPS-stimulated RAW 264.7 cells. Mar Drugs 5:151–156CrossRefPubMedPubMedCentralGoogle Scholar
  21. Oyadomari S, Mori M (2004) Roles of CHOP/GADD153 in endoplasmic reticulum stress. Cell Death Differ 11:381–389CrossRefPubMedGoogle Scholar
  22. Park S, Gwak J, Cho M, Song T, Won J, Kim DE, Shin JG, Oh S (2006) Hexachlorophene inhibits Wnt/β-catenin pathway by promoting Siah-mediated beta-catenin degradation. Mol Pharmacol 70:960–966CrossRefPubMedGoogle Scholar
  23. Park S, Yun E, Hwang IH, Yoon S, Kim DE, Kim JS, Na M, Song GY, Oh S (2014) Ilimaquinone and ethylsmenoquinone, marine sponge metabolites, suppress the proliferation of multiple myeloma cells by down-regulating the level of β-catenin. Mar Drugs 12:3231–3244CrossRefPubMedPubMedCentralGoogle Scholar
  24. Puthalakath H, O’Reilly LA, Gunn P, Lee L, Kelly PN, Huntington ND, Hughes PD, Michalak EM, McKimm-Breschkin J, Motoyama N, Gotoh T, Akira S, Bouillet P, Strasser A (2007) ER stress triggers apoptosis by activating BH3-only protein Bim. Cell 129:1337–1349CrossRefPubMedGoogle Scholar
  25. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC (2009) Multiple myeloma. Lancet 374:324–339CrossRefPubMedGoogle Scholar
  26. Rodriguez J, Quinoa E, Riguera R, Peters BM, Abrell LM, Crews P (1992) The structures and stereochemistry of cytotoxic sesquiterpene quinones from Dactylospongia elegans. Tetrahedron 48:6667–6680CrossRefGoogle Scholar
  27. Rubinfeld B, Albert I, Porfiri E, Fiol C, Munemitsu S, Polakis P (1996) Binding of GSK3beta to the APC-β-catenin complex and regulation of complex assembly. Science 272:1023–1026CrossRefPubMedGoogle Scholar
  28. Ryu MJ, Cho M, Song JY, Yun YS, Choi IW, Kim DE, Park BS, Oh S (2008) Natural derivatives of curcumin attenuate the Wnt/β-catenin pathway through down-regulation of the transcriptional coactivator p300. Biochem Biophys Res Commun 377:1304–1308CrossRefPubMedGoogle Scholar
  29. Sukhdeo K, Mani M, Zhang Y, Dutta J, Yasui H, Rooney MD, Carrasco DE, Zheng M, He H, Tai YT, Mitsiades C, Anderson KC, Carrasco DR (2007) Targeting the β-catenin/TCF transcriptional complex in the treatment of multiple myeloma. Proc Natl Acad Sci USA 104:7516–7521CrossRefPubMedPubMedCentralGoogle Scholar
  30. Tabas I, Ron D (2011) Integrating the mechanisms of apoptosis induced by endoplasmic reticulum stress. Nat Cell Biol 13:184–190CrossRefPubMedPubMedCentralGoogle Scholar
  31. Tetsu O, McCormick F (1999) β-Catenin regulates expression of cyclin D1 in colon carcinoma cells. Nature 398:422–426CrossRefPubMedGoogle Scholar
  32. Wodarz A, Nusse R (1998) Mechanisms of Wnt signaling in development. Annu Rev Cell Dev Biol 14:59–88CrossRefPubMedGoogle Scholar
  33. Yamaguchi H, Wang HG (2004) CHOP is involved in endoplasmic reticulum stress-induced apoptosis by enhancing DR5 expression in human carcinoma cells. J Biol Chem 279:45495–45502CrossRefPubMedGoogle Scholar
  34. Yao H, Ashihara E, Strovel JW, Nakagawa Y, Kuroda J, Nagao R, Tanaka R, Yokota A, Takeuchi M, Hayashi Y, Shimazaki C, Taniwaki M, Strand K, Padia J, Hirai H, Kimura S, Maekawa T (2011) AV-65, a novel Wnt/β-catenin signal inhibitor, successfully suppresses progression of multiple myeloma in a mouse model. Blood Cancer J 1:e43CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© The Pharmaceutical Society of Korea 2017

Authors and Affiliations

  • Seoyoung Park
    • 1
  • In Hyun Hwang
    • 2
  • Jiseon Kim
    • 1
  • Young-Hwa Chung
    • 3
  • Gyu-Young Song
    • 4
  • MinKyun Na
    • 4
    Email author
  • Sangtaek Oh
    • 1
    • 5
    Email author
  1. 1.Department of Bio and Fermentation Convergence Technology, BK21 PLUS programKookmin UniversitySeoulRepublic of Korea
  2. 2.College of PharmacyWoosuk UniversityWanjuRepublic of Korea
  3. 3.BK21+, Department of Cogno-Mechatronics EngineeringPusan National UniversityBusanRepublic of Korea
  4. 4.College of PharmacyChungnam National UniversityDaejeonRepublic of Korea
  5. 5.Department of Bio and Fermentation Convergence TechnologyKookmin UniversitySeoulRepublic of Korea

Personalised recommendations